Trial · NCT03593018
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 18 months after first randomisation (when 18 events will occur) | PFS using local assessment of progressive disease according to Lugano Response Criteria (2014) |
| Primary | Progression Free Survival (PFS) | 35 months after first randomisation (when 61 events will occur) | PFS using local assessment of progressive disease according to Lugano Response Criteria (2014) |
| Secondary | Overall survival (OS) | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | Overall survival |
| Secondary | PFS by the Independent Review Committee (IRC) | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | PFS by the Independent Review Committee |
| Secondary | Overall response rate | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | Percentage of Complete Response (CR)+ Partial Response (PR) among all patients |
| Secondary | Complete response rate (CRR) | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | Percentage of CR among all patients |
| Secondary | Duration of response (DoR) | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | Duration of response |
| Secondary | Time to response (TtR) | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | Time to response |
| Secondary | PFS 2 using local assessment of progressive disease | 40 months after first randomisation (when 57 deaths will occur) or 2 years after last randomisation | PFS 2 using local assessment of progressive disease |
| Secondary | Quality of Life Questionnaire (QLQ-C30) | 2 years after last randomisation | questionnaire at baseline and at least one follow-up |
| Secondary | Number of Serious Adverse Events (SAE) | 2 years after last randomisation | Treatment discontinuation, adverse events, deaths |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03593018/registered